Nicox's Ordinary Shareholder Meeting
...................................
April 22, 2014.
Sophia Antipolis, France.
Nicox S.A. (NYSE Euronext Paris: COX) has convened an ordinary shareholder meeting on Wednesday June 4, 2014 at 2:00 pm CET at the Hotel Mercure - rue Albert Caquot - 06560 Sophia Antipolis - France.
The documents mentioned in articles L.225-115, R. 225-81 and R. 225-83 of the French Code de commerce, including a proxy voting form, will be sent to shareholders upon written request. These documents will also be made available to shareholders at the headquarters and on the website of the Company (www.nicox.com) by May 14, 2014.
In the event the quorum is not reached on the first call, Nicox will convene a shareholder meeting on a second call on Wednesday June 18, 2014 at 2:00 pm CET at the Hotel Mercure - rue Albert Caquot - 06560 Sophia Antipolis - France.
...................................
About Nicox
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of therapies and diagnostic tools that can help people to enhance their sight. The Company's commercial portfolio and near-term pipeline already include several innovative diagnostic tests intended for eye care professionals, as well as a range of eye care products. Nicox's key proprietary asset in ophthalmology is latanoprostene bunod, a novel compound based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, currently in Phase 3 clinical development in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donors are under development, notably through partners.
Nicox is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets and an expanding international presence through partners. Nicox S.A. is listed on Euronext Paris (Compartment B: Mid Caps). For more information on Nicox or its products please visit www.nicox.com.
...................................
This communication may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.
Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2012 » filed with the French Autorité des Marchés Financiers (AMF) on April 2, 2014 and available on Nicox's website (www.nicox.com) and on the AMF's website (www.amf-france.org).
...................................
Contact:
Nicox Communications Corporate
Tel +33 (0)4 97 24 53 00 | communications@nicox.com
Nicox S.A.
Drakkar 2 | Bât D | 2405 route des Dolines | CS 10313 | Sophia Antipolis | 06560 Valbonne | France
T: +33 (0)4 97 24 53 00 | F: +33 (0)4 97 24 53 99
